USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Qubicaamf Europe S.p.a.

USPTO PatentsView assignee record - 7 granted patents across 3 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A63D (BOWLING GAMES, e.g. SKITTLES, BOCCE OR BOWLS; INSTALLATIONS THEREFOR; BAGATELLE OR SIMILAR GAMES; BILLIARDS).

7
Total patents granted
3
CPC technology areas
21.4
Avg claims per patent
-25%
5-year grant velocity

The verdict

According to USPTO PatentsView, Qubicaamf ranks #37,144 of 50,000 tracked US assignees by granted-patent volume, with 7 patents across 3 technology areas.

#37,144
of 50,000 US assignees by volume
Top 58%
by Innovation Score (32.8/100)
21.4
avg claims per patent
-25%
grant velocity, last 5 yrs

Portfolio overview

Qubicaamf Europe S.p.a. has been granted 7 US utility patents between 2016 and 2024, placing Qubicaamf Europe S.p.a. at #37,144 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.4 claims per patent with primary concentration in A63D (BOWLING GAMES, e.g. SKITTLES, BOCCE OR BOWLS; INSTALLATIONS THEREFOR; BAGATELLE OR SIMILAR GAMES; BILLIARDS). As a Foreign Corporation, Qubicaamf Europe S.p.a. is one of the more focused assignees in the PatentsView dataset. By volume, Qubicaamf sits between Quality Standards, Llc (7 patents, rank #37,103) and Qiagen Instruments Ag (7 patents, rank #37,111) - the closest US assignees by grant volume. The composite Innovation Score of 32.8/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 3 grants, compared with 4 in the 2015–2019 window, a -25% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Qubicaamf Europe S.p.a.'s 21.4 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 3 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Who files at Qubicaamf's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Qubicaamf holds 7 patents at rank #37,107, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Qubicaamf

By rank, the assignees closest to #37,107 in granted patent volume.

Leaders in A63D (Bowling Games)

Other assignees with the most granted patents in Qubicaamf's primary technology class.

Qubicaamf's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 Top 58% higher than 42% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 201620182019202020232024 1
USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
Qubicaamf Europe S.p.a. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 2 28.6%
2018 1 14.3%
2019 1 14.3%
2020 1 14.3%
2023 1 14.3%
2024 1 14.3%

Grant record at a glance

Portfolio Volume 7 grants
CPC subclasses 3
Avg. claims / grant 21.4
Velocity -25%

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#37,144

of 50,000 tracked assignees

Innovation Score

32.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Qubicaamf Europe S.p.a. rank among US patent assignees?
According to USPTO PatentsView (2015–2025 granted utility patents), Qubicaamf Europe S.p.a. ranks #37,144 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.
How many patents does Qubicaamf Europe S.p.a. hold?
Qubicaamf Europe S.p.a. holds 7 US utility patents granted between 2016 and 2024, spanning 3 technology areas.
What is Qubicaamf Europe S.p.a.'s Innovation Score?
Qubicaamf Europe S.p.a. has an Innovation Score of 32.8 out of 100 (top 58% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Qubicaamf Europe S.p.a. focus on?
Qubicaamf Europe S.p.a.'s top technology area is A63D (BOWLING GAMES, e.g. SKITTLES, BOCCE OR BOWLS; INSTALLATIONS THEREFOR; BAGATELLE OR SIMILAR GAMES; BILLIARDS) with 6 patents. Grants appear in 3 CPC subclasses total.
Is Qubicaamf Europe S.p.a.'s patent grant rate increasing or decreasing?
Qubicaamf Europe S.p.a.'s recent grant velocity is -25% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.
What does claim depth mean for Qubicaamf Europe S.p.a.'s patents?
Qubicaamf Europe S.p.a.'s patents average 21.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.
How is the Qubicaamf Europe S.p.a. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Qubicaamf's 7 grants land it in the top 58% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Qubicaamf ranks #37,144 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A63D - see who else leads that technology area. A63D leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.